Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. This development marks a significant step in the company’s global intellectual property strategy and could have important implications for the future of PTSD treatment.
The Canadian patent allowance is part of a broader intellectual property portfolio that Silo has been building around SPC-15. The company holds an exclusive license for the Canadian patent application through its agreement with Columbia University, which grants it rights to further develop, manufacture, and commercialize SPC-15 globally. Corresponding intellectual property has already been granted or is advancing in multiple international markets, including a recently granted European patent covering the same core invention. This international coverage helps protect the compound in key markets and may enhance its commercial value.
SPC-15 is an intranasal formulation designed to deliver a 5-HT4 receptor agonist directly to the brain, potentially offering a novel mechanism for treating PTSD and stress-related conditions. PTSD affects millions of people worldwide, and current treatments often have limited efficacy or significant side effects. Silo’s approach could provide a new option for patients who do not respond to existing therapies.
The company intends to utilize the FDA’s streamlined 505(b)(2) regulatory pathway for SPC-15. This pathway allows a drug to rely on existing safety and efficacy data from previously approved drugs, which can shorten clinical timelines and reduce development costs. If successful, this strategy could bring SPC-15 to market faster and at a lower cost than traditional drug development, potentially making it more accessible to patients in need.
The Canadian patent allowance is a key milestone for Silo as it continues to advance its pipeline. The company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. In addition to SPC-15, Silo is developing SP-26 for fibromyalgia and chronic pain, and has preclinical assets targeting Alzheimer’s disease and multiple sclerosis. These programs are conducted in collaboration with leading universities and laboratories, leveraging academic expertise to drive innovation.
With this patent allowance, Silo strengthens its position in the competitive landscape of psychiatric therapeutics. The company’s ability to secure intellectual property protection in multiple jurisdictions is crucial for attracting partners and investors, as it reduces the risk of competition and provides a foundation for future revenue streams. As Silo progresses SPC-15 through development, the global patent portfolio will be a key asset in its efforts to bring this promising treatment to patients worldwide.
For more information on Silo Pharma and its pipeline, visit the company’s newsroom at https://ibn.fm/SILO.
